Frazier Life Sciences Management L.P. Has $300.75 Million Stock Position in NewAmsterdam Pharma Company N.V. $NAMS

Frazier Life Sciences Management L.P. raised its holdings in NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) by 3.0% in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 16,607,074 shares of the company’s stock after purchasing an additional 490,656 shares during the period. NewAmsterdam Pharma accounts for about 12.0% of Frazier Life Sciences Management L.P.’s holdings, making the stock its 3rd biggest position. Frazier Life Sciences Management L.P. owned 14.79% of NewAmsterdam Pharma worth $300,754,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently bought and sold shares of the business. Deutsche Bank AG grew its stake in NewAmsterdam Pharma by 2,634.0% in the 1st quarter. Deutsche Bank AG now owns 72,397 shares of the company’s stock valued at $1,482,000 after buying an additional 69,749 shares in the last quarter. Aberdeen Group plc boosted its holdings in shares of NewAmsterdam Pharma by 110.5% in the first quarter. Aberdeen Group plc now owns 376,863 shares of the company’s stock worth $7,714,000 after acquiring an additional 197,803 shares during the period. American Century Companies Inc. grew its position in shares of NewAmsterdam Pharma by 52.6% in the first quarter. American Century Companies Inc. now owns 528,830 shares of the company’s stock valued at $10,825,000 after purchasing an additional 182,258 shares in the last quarter. Wellington Management Group LLP raised its stake in shares of NewAmsterdam Pharma by 53.0% during the 1st quarter. Wellington Management Group LLP now owns 3,541,975 shares of the company’s stock valued at $72,504,000 after purchasing an additional 1,226,852 shares during the period. Finally, OMERS ADMINISTRATION Corp lifted its holdings in NewAmsterdam Pharma by 83.9% during the 1st quarter. OMERS ADMINISTRATION Corp now owns 37,700 shares of the company’s stock worth $772,000 after purchasing an additional 17,200 shares in the last quarter. 89.89% of the stock is owned by institutional investors.

NewAmsterdam Pharma Price Performance

NAMS stock opened at $37.25 on Friday. The firm has a 50 day simple moving average of $37.18 and a two-hundred day simple moving average of $27.78. The stock has a market cap of $4.22 billion, a PE ratio of -18.17 and a beta of 0.05. NewAmsterdam Pharma Company N.V. has a one year low of $14.06 and a one year high of $42.00.

NewAmsterdam Pharma (NASDAQ:NAMS) last posted its quarterly earnings data on Wednesday, November 5th. The company reported ($0.41) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.03). The company had revenue of $0.35 million for the quarter, compared to the consensus estimate of $4.54 million. NewAmsterdam Pharma had a negative return on equity of 28.30% and a negative net margin of 627.59%. On average, research analysts expect that NewAmsterdam Pharma Company N.V. will post -1.75 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of research firms have weighed in on NAMS. HC Wainwright started coverage on NewAmsterdam Pharma in a report on Monday, October 20th. They set a “buy” rating and a $52.00 target price for the company. Wells Fargo & Company assumed coverage on shares of NewAmsterdam Pharma in a research note on Monday, August 25th. They set an “overweight” rating and a $45.00 price objective for the company. Royal Bank Of Canada upped their target price on shares of NewAmsterdam Pharma from $39.00 to $44.00 and gave the stock an “outperform” rating in a report on Thursday, November 6th. Needham & Company LLC raised their price target on shares of NewAmsterdam Pharma from $40.00 to $46.00 and gave the company a “buy” rating in a report on Wednesday, November 5th. Finally, Citigroup upped their price target on shares of NewAmsterdam Pharma from $42.00 to $50.00 and gave the stock a “buy” rating in a report on Friday, October 17th. Eight analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $45.30.

About NewAmsterdam Pharma

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.